Liquid biopsy

A Cancer Research UK team has developed a diagnostic platform that uses tumor-derived circulating DNA to noninvasively monitor a patient's response to therapy.¹ The researchers are now moving the technology into a hospital setting, where they will test its ability to diagnose ovarian cancer earlier than standard pelvic scans.

In cancer patients, 1%-10% of circulating or cell-free DNA (cfDNA) derives from tumor cells,² including fragments of mutated oncogenes such as RAS, p53 and phosphoinositide 3-kinase (PI3K).^3-6...